Glycoproteins

We are applying our technology to the development of either generic or biosimilar glycoprotein products. We believe that this technology can further be used in assisting pharmaceutical and biotechnology companies in developing improved and next-generation versions of their branded products by analyzing and modifying the protein mixture, and can also be used to engineer novel complex mixture drugs.

Low-Molecular-Weight Heparin (LMWH): a class of medication used to prevent blood clot formation. Glycoprotein: a large molecule composed of both a protein and a carbohydrate.

Our glycoprotein program is focused on extending our technology for the analysis of complex sugars to glycoproteins. The goal of the program is to facilitate the development of follow-on biologics, or biogeneric or biosimilar versions of major marketed glycoprotein products.